Tertiary structures of influenza virus proteins (matrix 2, neuraminidase, and RNA polymerase) and chemical formulas of influenza virus inhibitors. Tertiary.

Slides:



Advertisements
Similar presentations
1 Antiviral Drugs Limited selective toxicity –Viruses mostly use host cell machinery, so very few unique targets –Most drugs block steps that take place.
Advertisements

Antivirals Slackers Facts by Mike Ori. Disclaimer The information represents my understanding only so errors and omissions are probably rampant. It has.
80% Influenza A — H3N2 (some H1N1) 20 % influenza B (orthomyoxiviridae – seals and humans only) Deaths above epidemic threshold – 50% hospitalizations.
Influenza Sara Finestone April 8, The influenza virus causes 3-5 million cases of severe illness and up to 500,000 deaths annually.
Vaccines and Antivirals. Clinical Use of Interferon Therefore they have been used in the treatment of cancers of various types. Therefore they have been.
1 Inhibitors of Other Viruses A. RIBAVIRIN Ribavirin (Virazole) is a nucleoside analogue in which a triazolecarboxamide moiety is substituted on place.
Lecture 27 Pharmacology Flint et al., Chapter 19, pp. 725 – 757.
Antiviral Chemotherapy Discovery of antiviral drugs Targets of antiviral drugs.
Antiviral Agents Upton D. Allen. Outline of Presentation Herpes group agents Anti-influenza agents Anti-hepatitis agents Anti-RSV Immune response modifiers.
Antivirals for Influenza Yasir Waheed, PhD. Influenza is considered to be one of the life threatening infectious diseases. In some countries seasonal.
H1N1 (Swine Flu) By SierraLynn Johnson. Description of H1N1  H1N1 (Swine Flu) is a respiratory illness found in pigs or an infection cause by a virus.
Influenza A/H1N1 W. Rose H1N1 is a subtype of influenza type A Influenza types B and C also exist but less common, less infectious, and drift.
Antivirals. Structure of a Virus all viruses- o have a central core of DNA or RNA o surrounded by a coat(capsid) of packed protein units(capsomers) UNLIKE.
Medicines and Drugs Anti-virals Julia Barnes Anna Cruickshank.
Antiviral Drugs. Mechanism of Action Picornaviruses eg, polioviruses, cold viruses Block attachment molecule on host cell or pathogen Attachment antagonists.
ANTIVIRAL AGENTS FOR THE PREVENTION AND TREATMENT ON INFLUENZA.
Antiviral Agents, chapter 39 Different living organisms.
Who Knew? The Flu and YOU! By: Christine Antler and Erin Boyle.
 Recognition  Attachment  Penetration  Uncoating  Early protein synthesis  Nucleic acid synthesis  Late protein synthesis  Assembly  Release.
Two different therapeutic approaches for treating: A.A DNA virus (e.g. Herpes) B.An RNA virus (e.g. Influenza)
Antiviral drugs.
Viro100: Virology 3 Credit hours NUST Centre of Virology & Immunology
Antiviral agents Hamzeh Elayan
Antiviral Drugs Viruses are obligate intracellular parasites.
Antivirals Essential idea
Oseltamivir Neuraminidase inhibitor
Antiviral Medications
VIRAL INFLUENZA.
THE INFECTIOUS PROCESS FOR A VIRUS Despite their simplicity relative to bacteria, viruses still possess various biochemical targets for potential attack.
Antivirals Essential idea
Antiviral chemotherapy
Antiviral Drugs.
Guangdi Li, Erik De Clercq
Antiviral drugs Mr. OLORO JOSEPH..
Principles of Pharmacology The Pathophysiologic Basis of Drug Therapy
Antivirals Essential idea
Biology Copyright Pearson Prentice Hall.
Antiviral Drugs Viruses are obligate intracellular parasites.
Antiviral Review 22 November :45 PM.
Antiviral Agents.
Balance of Power in Host-Virus Arms Races
Figure 1 HCV life cycle and site of action of DAAs
Emerging Therapeutic Targets for Hepatitis C Virus Infection
Battling the Flu: Latest Advances in the Influenza Treatment Arsenal
Jean–Michel Pawlotsky, Stéphane Chevaliez, John G. McHutchison 
Volume 57, Issue 5, Pages (March 2015)
Key airway signaling pathways induced by respiratory viruses.
Diagram of AmpC from E. coli complexed with acylated ceftazidime (PDB accession number 1IEL) (265) created with Cn3CD, version 4.1 (available at
Examples of immune response disruption by respiratory viruses.
New therapies on the horizon for hepatitis C
Putative processing of the astrovirus nonstructural proteins expressed from ORF1a and ORF1b. Putative processing of the astrovirus nonstructural proteins.
Interaction of drug substrates and the AcrB-binding protomer analyzed with Autodock Vina docking software. Interaction of drug substrates and the AcrB-binding.
History of antiviral drugs approved between January 1959 and April History of antiviral drugs approved between January 1959 and April (A) Approved.
MexT-associated downregulation of oprD expression.
Antiviral drug groups for the treatment of 9 infectious diseases.
Good teaching is more a giving of right questions than a giving of right answers. – Josef Albers Viruses Chapter 19.
Mechanisms of drug actions during the viral life cycle.
Virus family, morphology, and transmission of HIV, HBV, HCV, HSV, HCMV, HPV, RSV, VZV, and influenza virus. Virus family, morphology, and transmission.
Structure of PrfA (A) and its target DNA sequences in PrfA-regulated promoters (B). Structure of PrfA (A) and its target DNA sequences in PrfA-regulated.
Selected host cell processes targeted by Dot/Icm effectors demonstrating the complexity of LCV biogenesis and maintenance as well as the broad range of.
Drug transport mechanism of AcrB.
Antiviral chemotherapy
Schematic representation of a rotavirus virion.
Tertiary structures of viral integrase and chemical formulas of HIV integrase inhibitors. Tertiary structures of viral integrase and chemical formulas.
Molecular phylogenetic analysis of RNA polymerase II largest-subunit protein sequences from various trichomonads, including D. fragilis. Molecular phylogenetic.
HCMV and HSV-1 DNA polymerase structures and chemical formulas of pyrophosphate analogues, 5-substituted 2′-deoxyuridine analogues, and nucleoside analogues.
Tertiary structures of HIV-1 reverse transcriptase and chemical formulas of NRTIs and NNRTIs. (A) HIV-1 RT complexed with dsDNA and zidovudine triphosphate.
Tertiary structures of HIV-1 protease and chemical formulas of HIV protease inhibitors. Tertiary structures of HIV-1 protease and chemical formulas of.
Functions of selected IFN-inducible proteins.
Human cytomegalovirus vaccine development strategies.
Presentation transcript:

Tertiary structures of influenza virus proteins (matrix 2, neuraminidase, and RNA polymerase) and chemical formulas of influenza virus inhibitors. Tertiary structures of influenza virus proteins (matrix 2, neuraminidase, and RNA polymerase) and chemical formulas of influenza virus inhibitors. (A) Tertiary structure of the influenza A virus matrix 2 protein in complex with amantadine (PDB accession number 2KAD). Movies that simulate the binding of approved antiviral drugs to viral or host proteins are available online (see http://www.virusface.com/). (B) Structure of influenza A virus neuraminidase in complex with zanamivir (PDB accession number 2HTQ). (C) Tertiary structure of influenza virus RNA polymerase in complex with RNA. The RNA polymerases of influenza A virus (left) (PDB accession number 3J9B) and influenza B virus (right) (PDB accession number 4WRT) are illustrated. The PA, PB1, and PB2 subunits of RNA polymerase (see structural details in reference 480) are shown in pink, orange, and gray, respectively. Ribavirin triphosphate targets the catalytic site of the RNA polymerase to inhibit viral replication. Note that the RNA polymerase of influenza A virus is a tetramer (480), but the complete tetramer structure of influenza virus RNA polymerase in complex with its inhibitors is still lacking. (D and E) Chemical formulas of amantadine and rimantadine, which target the matrix 2 protein of influenza virus. (F and G) Chemical formulas of ribavirin and favipiravir, which target the viral RNA polymerase of influenza virus. (H to K) Chemical formulas of zanamivir, laninamivir, peramivir, and oseltamivir, which target the viral neuraminidase of influenza virus. Erik De Clercq, and Guangdi Li Clin. Microbiol. Rev. 2016; doi:10.1128/CMR.00102-15